Publications by authors named "Christopher Pocock"

Claim this Profile
Q
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.
Maria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, Pip Patrick, June Warden, Christopher F E Pocock

Br J Haematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Michael L Wang, Wojciech Jurczak, Mats Jerkeman, Judith Trotman, Pier L Zinzani, Christopher Pocock

N Engl J Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Andrew M Evens, Joseph M Connors, Anas Younes, Stephen M Ansell, Won Seog Kim, Christopher Pocock

Haematologica· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphoid blast crisis after prolonged treatment-free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de-escalation during the COVID-19 pandemic.
Daniele Avenoso, Dragana Milojkovic, James Clark, Christopher Pocock, Victoria Potter

EJHaem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.
Gail J Roboz, Hartmut Döhner, Christopher Pocock, Herve Dombret, Farhad Ravandi

Haematologica· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Farhad Ravandi, Gail J Roboz, Andrew H Wei, Hartmut Döhner, Christopher Pocock

J Hematol Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Mary Gleeson, Nicholas Counsell, David Cunningham, Anthony Lawrie, Laura Clifton-Hadley, Christopher Pocock

Br J Haematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Andrew H Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris Afanasyev

N Engl J Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Richard E Clark, Fotios Polydoros, Jane F Apperley, Dragana Milojkovic, Katherine Rothwell, Christopher Pocock

Lancet Haematol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Andrew Davies, Thomas E Cummin, Sharon Barrans, Tom Maishman, Christoph Mamot, Christopher Pocock

Lancet Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Aytug Kizilors, Elena Crisà, Nicholas Lea, Roberto Passera, Syed Mian, Christopher Pocock

Lancet Haematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Jacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, Neil E Kay, Nishitha M Reddy, Christopher Pocock

Clin Lymphoma Myeloma Leuk· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
Richard E Clark, Fotios Polydoros, Jane F Apperley, Dragana Milojkovic, Christopher Pocock

Lancet Haematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.
Abraham M Varghese, Dena R Howard, Christopher Pocock, Andy C Rawstron, George Follows

Br J Haematol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
Mary Gleeson, Eliza A Hawkes, David Cunningham, Nick Chadwick, Nicholas Counsell, Christopher Pocock

Br J Haematol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of Stage IA classical Hodgkin lymphoma with FDG-avid tonsils.
Theodora Vatopoulou, Charles Lawson, Christopher Pocock

Br J Haematol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Simon Rule, Paul Smith, Peter W M Johnson, Simon Bolam, George Follows, Christopher Pocock

Haematologica· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C Byrd, Jennifer R Brown, Susan O'Brien, Jacqueline C Barrientos, Neil E Kay, Christopher Pocock

N Engl J Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Kirit M Ardeshna, Wendi Qian, Paul Smith, Nivette Braganca, Lisa Lowry, Christopher F E Pocock

Lancet Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
Peter Hillmen, John G Gribben, George A Follows, Donald Milligan, Hazem A Sayala, Christopher F E Pocock

J Clin Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.
Paul A Fields, William Townsend, Andrew Webb, Nicholas Counsell, Christopher Pocock

J Clin Oncol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.
Graham P Collins, Anne N Parker, Christopher Pocock, Irfan Kayani, Anna Sureda

Br J Haematol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
David Cunningham, Eliza A Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Christopher Pocock

Lancet· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
David Marin, Corinne Hedgley, Richard E Clark, Jane Apperley, Letizia Foroni, Christopher Pocock

Blood· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Peter Hillmen, Dena R Cohen, Kim Cocks, Andrew Pettitt, Hazem A Sayala, Christopher Pocock

Br J Haematol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis